FDA Inspection 1203599 — Cooperman Barnabas Medical Center Inc.
The FDA completed an inspection of Cooperman Barnabas Medical Center Inc. on Apr 20, 2023 in Livingston, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 20, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Livingston, NJ (United States)